These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3325254)

  • 21. [Comparative antibacterial activity of fleroxacin: selection frequencies and outer membrane proteins of resistant mutants].
    Cullmann W; Dechène M; Stieglitz M
    Immun Infekt; 1988 Aug; 16(4):152-8. PubMed ID: 3141267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ofloxacin: bactericidal effect in an in vitro pharmacokinetic model.
    Xerri L; Broggio R; Guerra L
    Chemioterapia; 1986 Apr; 5(2):83-7. PubMed ID: 3085961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents].
    Ohno I; Ida S
    Nihon Rinsho; 1987 Mar; 45(3):577-82. PubMed ID: 3298736
    [No Abstract]   [Full Text] [Related]  

  • 24. In vivo sequential selection of Escherichia coli with topoisomerase- and efflux-mediated misleading quinolone resistance phenotypes.
    Smati M; Emond JP; Arlet G; Tankovic J
    Microb Drug Resist; 2012 Feb; 18(1):19-22. PubMed ID: 22043806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients.
    Naber KG; Adam D; Kees F
    Drugs; 1987; 34 Suppl 1():44-50. PubMed ID: 3481328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigations on ofloxacin: antibacterial activity and influence on the immune system.
    Pulverer G; Peters G
    Infection; 1986; 14 Suppl 4():S245-7. PubMed ID: 3102386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation rates to 4-quinolone resistance.
    Smith JT
    Arzneimittelforschung; 1990 Jan; 40(1):65-8. PubMed ID: 2111135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae.
    Shah PM; Schäfer V; Hubener T; Metz C; Stille W
    Drugs; 1987; 34 Suppl 1():9-13. PubMed ID: 3481332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
    Linde HJ; Lehn N
    J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
    Soussy CJ; Deforges L; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280).
    Tsukamura M
    Am Rev Respir Dis; 1985 Mar; 131(3):348-51. PubMed ID: 3919625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.
    Appelbaum PC; Spangler SK; Tamarree T
    Chemotherapy; 1988; 34(1):40-5. PubMed ID: 3127127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Cullmann W; Stieglitz M; Baars B; Opferkuch W
    Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ofloxacin therapy of difficult-to-treat infections due to multiresistant organisms.
    el-Baz W; Osman L; Abd-el-Hamid T; el-Bokl M; Sabbour MS
    Chemioterapia; 1987 Apr; 6(2):129-33. PubMed ID: 3474079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies on the ofloxacin resistance of tubercle bacilli].
    Tsukamura M; Mizuno S
    Kekkaku; 1985 Oct; 60(10):517-21. PubMed ID: 3935845
    [No Abstract]   [Full Text] [Related]  

  • 38. Ofloxacin: in-vitro activity against clinical isolates.
    Grima P
    Chemioterapia; 1985 Dec; 4(6):434-5. PubMed ID: 3938347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic effect of ofloxacin on mice challenged by ofloxacin-resistant Mycobacterium bovis strains].
    Tsukamura M
    Kekkaku; 1987 Apr; 62(4):235-8. PubMed ID: 3306084
    [No Abstract]   [Full Text] [Related]  

  • 40. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.